BB Biotech AG

BB Biotech AG

BB Biotech AG

Overview
Date Founded

1993

Headquarters

Schwertstrasse 6,Schaffhausen, Zurich 8200

Type of Company

Public

Industries

Trusts & Funds
Investment Services & Portfolio Management

Company Description

BB Biotech AG is a closed-end investment fund, which engages in investing in biotechnology companies. It focuses on the development and commercialization of novel drugs sectors. The company was founded on November 9, 1993 and is headquartered in Schaffhausen, Switzerland.

Contact Data
Trying to get in touch with decision makers at BB Biotech AG? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Paths to BB Biotech AG
Potential Connections via
Relationship Science
You
BB Biotech AG
Owners & Shareholders
Details Hidden

BlackRock AM Schweiz is an active, risk-aware manager which offers clients a range of investment solutions across asset classes and regions, including equity, fixed-income, multi-asset, money market, index, absolute return, natural resources and equity income.The firm seeks to combine the global investment expertise of BlackRock for investors in Switzerland.

Details Hidden

SLW is an active, holistic manager which combines a conventional and a target return, volatility-managed approach to preserve and generate wealth. Their conventional approach invests in conventional asset classes like equities, bonds and real estate and aims to outperform the market or an agreed benchmark, while their target return approach is broadly diversified, aiming to deliver specific target returns.The firm takes a global investment approach, aiming to identify long-term drivers of change. Their analysts conduct fundamental research across markets. They manage money using a ''single-portfolio'' approach, investing directly across asset classes, aiming to invest in an appropriate combination of long-term return-seeking assets and tactical, risk-offsetting positionsTheir Multi Asset Investment Team provides input to their strategic asset allocation and research analysts conduct fundamental analysis. They control risk throughout the investment process through ''intelligent diversification,' investing with conviction across stocks and asset classes while not diversifying needlessly. Their Private Client Investment Team identifies and assesses potential investments and adjusts the model portfolio for specific client goals.SLW manages the target return, volatility-managed portfolios across a range of asset classes and regions, aiming to deliver consistently smoother returns. They invest a portion of the portfolio in the Strategic Investment Allocation Fund to increase diversification, improve returns and reduce overall volatility. They diversify risk by investing across asset classes, regions and strategies and utilize sophisticated risk analysis systems to monitor every portfolio's exposure to different risk factors and levels of risk. Their Investment Committee carries out the research and risk management processes.

Details Hidden

UBP-GI's investment objective is aimed at capital preservation and seeks absolute returns. They are active investment managers. The firm utilizes proprietary instruments, investment research and draws from their network of experts as part of their decision-making process.They construct portfolios reflecting their clients' risk and return profile, encompassing the conservative to aggressive investor. They may combine assets that range from traditional to structured investments across investment themes and geographic regions. They offer a concentrated number of compartments in equities, bonds and money markets.Multi-management funds selection is driven by both qualitative and quantitative analysis. The qualitative process is based on primary research. The quantitative analysis consists of three stages. First, performance profiles in different market phases are segmented. Then, each fund is analyzed individually using a proprietary tool which develops risk reports for each portfolio. Finally, a weighting model is applied to ensure diversification and balance of the final portfolio.Through UBP's worldwide network, UBP-GI provides access to asset managers in Europe, Asia and the US.

Recent Transactions
Details Hidden

BB Biotech AG issued EUR Ordinary Shares

Transaction Advisors
Global Coordinator

Advised onBB Biotech AG issued EUR Ordinary Shares

Key Stats and Financials As of 2019
Market Capitalization
$2.69B
Total Enterprise Value
$271M
Earnings Per Share
$12.23
Revenue
$241M
Net Profit
$677M
EBITDA
$679M
EBITDAMargin
282%
Total Debt
$150M
Total Equity
$3.39B
Enterprise Value Sales
1.12x
Enterprise Value EBITDAOperating
0.4x
TEVNet Income
0.4x
Debt TEV
0.55x
Three Year Compounded Annual Growth Rate Of Revenue
174.99%
Five Year Compounded Annual Growth Rate Of Revenue
1.71%
Investors
Details Hidden

Life Peer at United Kingdom House of Lords

Details Hidden

Life Peer at United Kingdom House of Lords

Details Hidden

Life Peer at United Kingdom House of Lords

Suppliers
Bellevue Group AG Investment Banking & Brokerage | Kusnacht, Switzerland

Bellevue Group AG engages in the provision of asset management and wealth management. It operates through the Bank am Bellevue and Asset Management segments. The Bank am Bellevue segment offers first-class wealth and investment advisory services with a special focus on entrepreneurial private clients. The Asset Management segment focuses on the healthcare sector and in other special themes such as owner-managed companies, as well as successful holistic investment strategies across all traditional asset classes. The company was founded by Hans-Jörg Graf in 1993 and is headquartered in Kusnacht, Switzerland.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by BB Biotech AG. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of BB Biotech AG's profile does not indicate a business or promotional relationship of any kind between RelSci and BB Biotech AG.